In 2023, the ESMO published preliminary results of first-line therapy with sunvozertinib in patients with EGFR ex20ins mutant advanced NSCLC, indicating an encouraging ORR of 78.6% for first-line treatment with sunvozertinib monotherapy exceeding 70%, and a median PFS of more than one year. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.